创新药板块回暖，指数涨超2%，恒生创新药ETF（159316）近5个交易日持续“揽金”

Core Viewpoint - The Hong Kong innovative drug sector has rebounded after a period of adjustment, with the Hang Seng Innovative Drug Index rising by 2.0% as of 14:00, indicating renewed investor interest in this segment [1]. Group 1: Market Performance - The Hang Seng Innovative Drug Index saw significant gains, with stocks such as Ascentage Pharma-B rising over 5%, and both 3SBio and Tonghua Dongbao Pharmaceutical-B increasing by more than 4% [1]. - The Hang Seng Innovative Drug ETF (159316) has experienced a net inflow of approximately 400 million yuan over the past five trading days, reflecting positive market sentiment [1]. Group 2: Upcoming Events - The 2025 European Society for Medical Oncology (ESMO) annual meeting is scheduled to take place from October 17 to October 21 in Berlin, Germany, which is expected to showcase several significant clinical research results, potentially boosting market interest in innovative drug assets [1]. Group 3: Index Composition - The Hang Seng Innovative Drug Index has excluded CXO companies in its compilation scheme, making it the first index with a "100% purity" focus on innovative drugs, accurately reflecting the overall performance of China's innovative pharmaceutical companies [1]. - The Hang Seng Innovative Drug ETF (159316) is currently the only product tracking this index, providing investors with a precise opportunity to capitalize on the development of the innovative drug industry [1].